Product Development Progress Update: Indonesia Cosmetics Collaboration with PT PARVA CANDELA
Two initial product candidates identified under the GENRÊVER and HAKUA brands — a premium UV cream (SPF50+ / PA++++) and a moisturizing gel featuring HA4; production targeted to commence within 2026
Key Facts
- Company
- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.
- Ticker
- Nasdaq: BIOT
- Announcement Date
- Category
- NEWS
- Source
- Official BIOT announcement
Tokyo, Japan – September 4, 2026 | Detailed companion to the Company’s operational update press release of the same date
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) (the “Company” or “Instinct Bio”) today provided a progress update on its Indonesia cosmetics collaboration with PT PARVA CANDELA (“PARVA”), announced on August 10, 2026. Following joint product planning, market analysis and product development work, the Company and PARVA have identified two initial cosmetic product candidates for the Indonesian market under the GENRÊVER and HAKUA brands, and development of both is underway. Production is targeted to commence within 2026, subject to product development completion, regulatory compliance and manufacturing readiness.
This page explains the reasoning behind the product choices, the formulation approach, the regulatory pathway — including Indonesia’s halal certification requirement — and where the project stands today.
“Made in Indonesia, Powered by Japanese Formulation Expertise”
The collaboration in one view
What PARVA brings
Local manufacturing capability in Indonesia, a domestic sales network, and market understanding — including the consumer and competitive analysis that informed the product selection.
What Instinct Bio brings
Japanese formulation expertise developed over many years, the GENRÊVER and HAKUA brands, brand development capability, and a quality-control framework.
What it produces
Cosmetics made in Indonesia for the Indonesian market first — with halal certification as a design requirement — and a foundation for potential ASEAN expansion, subject to regulatory approvals.
Progress since August 10, 2026
Since the collaboration was announced, the Company and PARVA have jointly analyzed four things: consumer needs, market conditions, sales channels and competing products in Indonesia. The analysis was led on the ground by PARVA and reviewed by the Company’s product planning team in Japan.
Two findings shaped the product decision. First, the UV care category — used every day and repurchased frequently — is a key driver of growth in the Indonesian skincare market. Second, consumers in a hot, humid climate place unusual weight on texture: a product that protects well but feels heavy is simply not used daily. The Company therefore chose a high-performance UV cream as Product No.1, with texture treated as a core specification rather than an afterthought, and began development of a moisturizing gel as Product No.2 to pair with it.
Product development update
Product No.1Premium UV CreamSPF50+ / PA++++
Development concept. Three pillars: UV protection, high moisturization, and a comfortable texture suited to daily use in a tropical climate.
Protection. SPF50+ / PA++++ — the highest UV protection ratings under the Japanese labelling system — has been confirmed through testing. SPF describes protection against UVB (the rays that cause sunburn); PA describes protection against UVA (the rays associated with photo-ageing). Indonesia sits on the equator and receives high UV levels throughout the year, so year-round daily protection, not seasonal use, is the design assumption.
Moisture and feel. The formulation targets a lightweight, non-greasy finish that can be worn under make-up and reapplied during the day, while maintaining moisturization. Formula optimization is in progress to balance protection, moisture and feel for local skin and climate conditions.
Formulation base. The product draws on the formulation expertise the Company has developed in Japan over many years, adapted to the Indonesian market.
Product No.2Moisturizing Gel featuring HA4
Key ingredient. HA4 is a low-molecular-weight hyaluronic acid developed in Japan. Conventional hyaluronic acid is a large molecule that forms a moisture-holding film on the skin surface; HA4 is a far smaller molecule designed to deliver moisture to the stratum corneum — the outermost layer of the skin.
Development concept. A light, refreshing gel texture suited to a humid climate, designed to be used together with the UV cream as a simple two-step daily routine: moisturize, then protect.
Status. Formulation development is in progress. Further details, including brand assignment and packaging, will be disclosed as development progresses.
Market positioning
In planning the products, the Company reviewed PARVA’s analysis of leading UV and moisturizing products and brands in Indonesia — their price points, textures, claims and channels. The products are not designed to imitate the market leaders. They are designed as distinctive premium offerings that combine the Company’s Japanese formulation technology with Japanese-developed ingredients, at a quality level the Company believes is not yet widely available from locally manufactured products, and positioned for the Indonesian upper-middle-income consumer.
Regulatory pathway: BPOM, CPKB and halal
Cosmetics sold in Indonesia must be notified to BPOM (Badan Pengawas Obat dan Makanan, the Indonesian Food and Drug Authority) and manufactured under CPKB, Indonesia’s good manufacturing practice standard for cosmetics. In addition, from October 17, 2026, halal certification becomes mandatory for cosmetics sold in Indonesia. The Company is treating halal certification not as an add-on but as a design requirement from the first formulation — ingredient selection, manufacturing process and documentation are being prepared with certification in mind.
Requirement — What it covers — Status
BPOM notification — Product registration with the Indonesian Food and Drug Authority before sale — Preparation planned
CPKB (cosmetic GMP) — Manufacturing standard for the production facility — Manufacturing preparation in progress
Halal certification — Mandatory for cosmetics sold in Indonesia from October 17, 2026 — Preparation planned
Regulatory timelines are outside the Company’s control. All targeted dates are subject to obtaining the required registrations and certifications.
Manufacturing approach
Products will be manufactured in Indonesia at PARVA’s facility. The Company’s role is to supply the formulations and the quality-control framework: specifications, ingredient standards and manufacturing procedures follow the Company’s Japanese practice, and PARVA’s facility is being prepared to produce to those standards under CPKB. This combination — Indonesian manufacturing, Japanese specifications — is what the collaboration’s concept, “Made in Indonesia, Powered by Japanese Formulation Expertise,” means in practice.
Beyond Indonesia: the ASEAN pathway
Indonesia, with approximately 280 million people, is the world’s largest Muslim-majority market. Halal-certified products developed for Indonesia are, by design, positioned for potential export to neighboring ASEAN markets (approximately 680 million people) and other Muslim-majority markets, subject to the regulatory requirements of each jurisdiction. This is why the Company regards the first two products as more than two SKUs: they are the first proof of a repeatable model — formulate in Japan, manufacture and certify in Indonesia, sell in Indonesia first and then more widely.
Population figures are public statistics. The Company does not provide revenue or unit forecasts for these products.
Current project status
Project item — Current status
Strategic collaboration announced (August 10, 2026) — Completed
Indonesian market analysis (consumers, market, channels, competitors) — Completed
Product category selection — Completed
Product No.1 (UV cream) decision and SPF/PA testing — Completed
Product No.1 formula optimization — In progress
Product No.1 prototype development — In progress
Product No.2 (HA4 moisturizing gel) formulation development — In progress
Manufacturing preparation at PARVA facility (production targeted within 2026) — In progress
Packaging specification — In progress
BPOM notification preparation — Planned
Halal certification preparation — Planned
Commercial launch preparation — Planned
Next milestones
Timing is subject to development results and regulatory processes.
・Completion of prototypes for both products
・Finalization of formulation and packaging specifications
・BPOM notification and halal certification processes
・Pilot production, followed by commencement of production (targeted within 2026)
・Commercial launch preparation, including brand and channel planning with PARVA
・Announcement of Product No.2 details as development progresses
Questions investors have asked
Why start with a UV cream rather than a broader range? Because it is the category the market analysis identified as the growth driver, it is used daily, and it is a demanding product to make well — a credible UV cream establishes the brand’s quality position before the range widens. Is HA4 in both products? No. HA4 is the key ingredient of Product No.2, the moisturizing gel. The UV cream is built on the Company’s existing formulation expertise. Which brand — GENRÊVER or HAKUA — will each product carry? Both brands are licensed for the collaboration. Brand assignment for each product will be announced as launch preparation progresses. Are there sales targets? The Company does not publish revenue or unit forecasts for these products. Progress will be reported by milestone. What could delay production? Principally regulatory timelines (BPOM notification, halal certification), development outcomes, and manufacturing readiness. See the Forward-Looking Statements section below.
Comment from the Chairman and CEO
“Since announcing our collaboration on August 10, the Company and PARVA have advanced market analysis and product planning, and as a result we have identified our first two product candidates for the Indonesian market under the GENRÊVER and HAKUA brands and begun development of both. Our first product will be a high-performance premium UV cream, followed by a moisturizing gel featuring HA4, both built on our Japanese formulation expertise. We do not consider an announcement to be the end of a project. We intend to commercialize each initiative step by step, and to keep our shareholders and investors informed of our progress on an ongoing basis,” said Tomoki Nagano, Chairman and Chief Executive Officer of Instinct Bio.
GENRÊVER brand site
Learn more
For photos, product details and the latest on GENRÊVER, visit the GENRÊVER brand site
www.genrever.com
Related Press release (September 4, 2026): INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives — [IR page link] Indonesia Growth Platform — Operational Update (detailed article) — [link] INVITRX Collaboration Update: GENRÊVER — Made in the U.S., Sold in the U.S. — [link] August 10, 2026 — Strategic collaboration with PT PARVA CANDELA — [link]
About Instinct Bio
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) is a biotechnology company focused on regenerative medicine, wellness-related technologies, and therapeutic platform development. Website: https://instinct-biot.com/
Forward-Looking Statements
This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the development, registration, certification, production and commercial launch of products under the Company’s collaboration with PT PARVA CANDELA, the expected benefits of the collaboration, and potential expansion into other markets. Words such as “targets,” “intends,” “designed to,” “plans,” “will” and similar expressions identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties, including the outcome of product development and testing; the Company’s ability to obtain BPOM notification, halal certification and other regulatory approvals in Indonesia and other jurisdictions on a timely basis or at all; manufacturing readiness; consumer acceptance; competition; the negotiation of definitive agreements; the Company’s relationship with PARVA; and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that the products described herein will be launched, or that the collaboration will generate revenue or profit. Forward-looking statements speak only as of the date of this article, and the Company undertakes no obligation to update them except as required by law.
Product descriptions are provided for informational purposes, describe development objectives, and are subject to change. The products are not yet available for sale. This article does not constitute an offer to sell or a solicitation of an offer to buy any securities.
Contact Information INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. Email: ir@instinct-bro.com Website: https://instinct-biot.com/ Sign up for email alerts on press releases, SEC filings and events at instinct-biot.com/investors.
Source Documents
Follow @BIOT_jp on X for company news and published IR updates.
